These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31465470)

  • 1. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
    Deniz B; Ambavane A; Yang S; Altincatal A; Doan J; Rao S; Michaelson MD
    PLoS One; 2019; 14(8):e0215761. PubMed ID: 31465470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
    Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
    Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
    Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
    Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H
    J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
    Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
    Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
    Villa G; Hernández-Pastor LJ
    BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
    Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
    J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
    Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
    [No Abstract]   [Full Text] [Related]  

  • 13. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
    Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.
    Wan XM; Peng LB; Ma JA; Li YJ
    Cancer; 2017 Jul; 123(14):2634-2641. PubMed ID: 28301684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
    Ambavane A; Yang S; Atkins MB; Rao S; Shah A; Regan MM; McDermott DF; Michaelson MD
    Immunotherapy; 2020 Jan; 12(1):37-51. PubMed ID: 31992108
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
    Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
    Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
    Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
    Front Public Health; 2022; 10():954264. PubMed ID: 36159269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.